Floatz logo

Ipilimumab

Effects of Immunotherapy

Radiotherapiemonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Effects of Immunotherapy cohort.

Asset / SponsorPhaseRating
TIL
Shanghai Juncell Therapeutics
Phase 1/2CCC
Alpha-Interferon
Leiden University
Phase 1/2CCC
Recombinant Wt1 Antigen-Specific Cancer Immunotherapeutic
Jules Bordet Institute
Phase 1/2CCC
Nivolumab
Leiden University
Phase 1/2CCC
Geniusvac-Mel4
University Hospital, Grenoble
Phase 1CC

View all 10 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →